The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice

Journal of Clinical Investigation

Volumn 115, Issue 8, 2005, Pages 2159-2168

  Schessl, Christina ^a,b   Rawat, Vijay P S ^a,b   Cusan, Monica ^a,b   Deshpande, Aniruddha ^a,b   Kohl, Tobias M ^a,b   Rosten, Patricia M ^c   Spiekermann, Karsten ^a,b   Humphries, R Keith ^c,d   Schnittger, Susanne ^b   Kern, Wolfgang ^b   Hiddemann, Wolfgang ^a,b   Quintanilla Martinez, Leticia ^a   Bohlander, Stefan K ^a,b   Feuring Buske, Michaela ^a,b   Buske, Christian ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ACUTE LEUKEMIA; ADULT; AML1 ETO GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE FUSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE MODELS, ANIMAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOPOIESIS; MALE; MICE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 23644454231     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24225     Document Type: Article

References (54)

1. Look, A.T. 1997. Oncogenic transcription factors in the human acute leukemias. Science. 278:1059-1064.
2. Rowley, J.D. 1999. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36:59-72.
3. Gilliland, D.G., and Tallman, M.S. 2002m Focus on acute leukemias. Cancer Cell. 1:417-420.
4. Schnittger, S., et al. 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 100:59-66.
5. Gilliland, D.G. 2002. Molecular genetics of human leukemias: new insights into therapy [review]. Semin. Hematol. 39:6-11.
6. Higuchi, M., et al. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human. t(8;21) acute myeloid leukemia. Cancer Cell. 1:63-74.
7. Yuan, Y., et al. 2001. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. U. S. A. 98:10398-10403.
8. de Guzman, G.G., et al. 2002. Hematopoietic stern cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol. Cell. Biol. 22:5506-5517.
9. Fenske, T.S., et al. 2004. Stem cell expression of the AML1/ETO fusion protein induces a myeloptoliferative disorder in mice. Proc. Natl. Acad. Sci. U. S. A. 101:15184-15189.
10. Nucifora, G., et al. 1993. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood. 81:883-888.
11. Downing, J.R. 1999. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br. J. Haematol. 106:296-308.
12. Peterson, L.F., and Zhang, D.E. 2004. The 8;21 translocation in leukemogenesis. Oncogene. 23:4255-4262.
13. Wang, Q., et al. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 93:3444-3449.
14. Sun, W., and Downing, J.R. 2004. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs, while simultaneously inducing an increase in more mature progenitors. Blood. 104:3565-3572.
15. Licht, J.D. 2001. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene. 20:5660-5679.
16. Pabst, T., et al. 2001. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7:444-451.
17. Mulloy, J.C., et al. 2002. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 99:15-23.
18. Schwieger, M., et al. 2002. AML1-ETO inhibits maturation of multiple lymphobematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J. Exp. Med. 196:1227-1240.
19. Rhoades, K.L., et al. 2000. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood. 96:2108-2115.
20. Nucifora, G., Larson, R.A., and Rowley, J.D. 1993. Persistence of the 8;21 translocation in patients wich acute myeloid leukemia type M2 in long-term remission. Blood. 82:712-715.
21. Miyamoto, T., Weissman, I.L., and Akashi, K. 2000, AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc. Natl. Acad. Sci. U. S. A. 97:7521-7526.
22. Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414:105-111.
23. Miyamoto, T., et al. 2002. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev. Cell. 3:137-147.
24. Tiacci, E., et al. 2004. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res. 64:7399-7404.
25. Kelly, L.M., et al. 2002. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 99:8283-8288.
26. Kelly, L.M., et al. 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model Blood. 99:310-318.
27. Ono, R., et al. 2005. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Invest. 115:919-929. doi:10.1172/JCI200522725.
28. Armstrong, S.A., et al. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30:41-47.
29. Armstrong, S.A., et al. 2004. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 103:3544-3546.
30. Taketani, T., et al. 2004. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy Blood. 103:1085-1088.
31. Grisolano, J.L., O'Neal, J., Cain, J., and Tomasson, M.H. 2003. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc. Natl. Acad. Sci. U. S. A. 100:9506-9511.
32. Levis, M., et al. 2005. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood. doi:10.1182/blood-2004-05-1902.
33. Boissel, N., et al. 2004. Incidence and prognosis of RTKs and RAS mutations in CBF AML. A retrospective study of French adult ALFA and pediatric LAME trials [abstract]. Blood. 103:2022.
34. Cairolij R., et al. 2004. Prognostic impact of C-Kit mutations in core binding factor-leukemia [abstract]. Blood. 103:2013.
35. Wang, Y.Y., et al. 2005. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc. Natl. Acad. Sci. U. S. A. 102:1104-1109.
36. Bennett, J.M., et al. 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33:451-458.
37. Harris, N.L., et al. 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:3835-3849.
38. Schnittger, S., et al. 2003. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification effusion transcripts. Blood. 102:2746-2755.
39. Schnittger, S., Wormann, B., Hiddemann, W., and Griesinger, F. 1998. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood. 92:1728-1734.
40. Spiekermann, K., et al. 2002. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood. 100:3423-3425.
41. Rawat, V.P., et al. 2004. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 101:817-822.
42. Riley, J., et al. 1990. A novel, rapid method for the isolation of terminal sequences from yeast artificial chromosome (YAC) clones. Nucleic Acids Res. 18:2887-2890.
43. Imren, S., et al. 2004. High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114:953-962. doi:10.1172/JCI200421838.
44. Kern, W., et al. 2004. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 104:3078-3085.
45. Pineault, N., et al. 2003. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 101:4529-4538.
46. Griffith, J., et al. 2004. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13:169-178.
47. Lenny, N., Meyers, S., and Hiebert, S.W. 1995. Functional domains of the t(8;21) fusion protein, AML-1/ETO. Oncogene. 11:1761-1769.
48. Spiekermann, K., et al. 2003. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 101:1494-1504.
49. Spiekermann, K., Faber, F., Voswinckel, R., and Hiddemann, W. 2002. The protein tyrosine kinase inhibitor SU56H inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp. Hematol. 30:767-773.
50. Stirewalt, D.L., and Radich, J.P. 2003. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer. 3:650-665.
51. Lyman, S.D., et al. 1993. Molecular cloning of a ligand for the flt3/flk-2 cyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 75:1157-1167.
52. Carow, C.E., et al. 1996. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 87:1089-1096.
53. Kogan, S.C., et al. 2002. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 100:238-245.
54. Morse, H.C., 3rd, et al. 2002. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 100:246-258.